Rockefeller Capital Management
NTLA icon

Rockefeller Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Rockefeller Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4M Buy
141,890
+367
+0.3% +$5.14K ﹤0.01% 1298
2026
Q1 		$1.81M Buy
141,523
+1,305
+0.9% +$16.6K ﹤0.01% 1352
2025
Q4 		$1.26M Buy
140,218
+2,277
+2% +$31.3K ﹤0.01% 1458
2025
Q3 		$2.38M Buy
137,941
+103
+0.1% +$1.27K ﹤0.01% 1095
2025
Q2 		$1.29M Hold
137,838
– – ﹤0.01% 1249
2025
Q1 		$980K Hold
137,838
– – ﹤0.01% 1268
2024
Q4 		$1.61M Buy
137,838
+61,800
+81% +$964K ﹤0.01% 1094
2024
Q3 		$1.56M Sell
76,038
-24,876
-25% -$574K ﹤0.01% 1084
2024
Q2 		$2.26M Buy
100,914
+24,569
+32% +$585K 0.01% 934
2024
Q1 		$2.1M Buy
76,345
+19,866
+35% +$552K 0.01% 992
2023
Q4 		$1.72M Buy
56,479
+9,968
+21% +$286K 0.01% 965
2023
Q3 		$1.47M Buy
46,511
+9,658
+26% +$375K 0.01% 956
2023
Q2 		$1.5M Buy
36,853
+4,704
+15% +$191K 0.01% 945
2023
Q1 		$1.2M Buy
32,149
+8,788
+38% +$345K 0.01% 998
2022
Q4 		$815K Sell
23,361
-7,129
-23% -$339K ﹤0.01% 1084
2022
Q3 		$1.71M Buy
30,490
+7,958
+35% +$494K 0.01% 815
2022
Q2 		$1.17M Buy
22,532
+642
+3% +$32.6K 0.01% 947
2022
Q1 		$1.59M Buy
21,890
+6,814
+45% +$577K 0.01% 883
2021
Q4 		$1.78M Buy
15,076
+11,669
+343% +$1.46M 0.01% 844
2021
Q3 		$457K Buy
3,407
+2,727
+401% +$413K ﹤0.01% 1295
2021
Q2 		$109K Buy
680
+54
+9% +$4.21K ﹤0.01% 1767
2021
Q1 		$50K Buy
626
+253
+68% +$17K ﹤0.01% 1891
2020
Q4 		$20K Buy
373
+48
+15% +$1.74K ﹤0.01% 2015
2020
Q3 		$6K Buy
+325
New +$6.78K ﹤0.01% 2163
2020
Q1 		– Sell
-7
Closed – – 2444
2019
Q4 		$0 Buy
+7
New +$97 ﹤0.01% 2159

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Rockefeller Capital Management's NTLA Position: Q2 2026 in Review

Rockefeller Capital Management increased its Intellia Therapeutics (NTLA) stake by 0.26% in Q2 2026, buying an estimated $5.14K and bringing the position to 141,890 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

Rockefeller Capital Management first reported a position in NTLA in Q4 2019 and has held it in 25 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Rockefeller Capital Management held 141,890 shares of Intellia Therapeutics worth $2.4M as of Q2 2026.
  • Rockefeller Capital Management bought 367 Intellia Therapeutics shares in Q2 2026, an estimated $5.14K.
  • Intellia Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1298 holding.
  • Rockefeller Capital Management first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.